Vertex Pharmaceuticals Incorporated (VRTX)
USD 472.37
(-0.46%)
USD 472.37
(-0.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.6 Billion USD | -9.52% |
| 2022 | 4.43 Billion USD | 55.81% |
| 2021 | 2.91 Billion USD | -12.52% |
| 2020 | 3.28 Billion USD | 118.68% |
| 2019 | 1.56 Billion USD | 119.83% |
| 2018 | 706.78 Million USD | 112.93% |
| 2017 | 103.25 Million USD | 1931.88% |
| 2016 | 75.46 Million USD | 103.24% |
| 2015 | -411.25 Million USD | 22.57% |
| 2014 | -598.75 Million USD | -221.1% |
| 2013 | -554.75 Million USD | 11983.19% |
| 2012 | 42.46 Million USD | -98.12% |
| 2011 | 133.93 Million USD | 133.48% |
| 2010 | -704.89 Million USD | -22.01% |
| 2009 | -598.87 Million USD | -18.77% |
| 2008 | -426.18 Million USD | -20.85% |
| 2007 | -385.21 Million USD | -87.27% |
| 2006 | -199.51 Million USD | -122.04% |
| 2005 | -114.44 Million USD | 12.48% |
| 2004 | -107.59 Million USD | -56.37% |
| 2003 | -264.52 Million USD | 29.4% |
| 2002 | -123.05 Million USD | -290.56% |
| 2001 | -97.13 Million USD | -64.36% |
| 2000 | -24.65 Million USD | 55.02% |
| 1999 | -44.3 Million USD | -16.85% |
| 1998 | -43.2 Million USD | -78.85% |
| 1997 | -15.6 Million USD | 7.69% |
| 1996 | -36.3 Million USD | 40.28% |
| 1995 | -22.8 Million USD | -36.06% |
| 1994 | -17.2 Million USD | -662.16% |
| 1993 | 5.1 Million USD | 140.22% |
| 1992 | -7.2 Million USD | -100.0% |
| 1991 | -3.8 Million USD | 7.32% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.18 Billion USD | 10.34% |
| 2024 Q3 | 1.11 Billion USD | 138.61% |
| 2024 Q2 | -3.47 Billion USD | -347.75% |
| 2023 FY | - USD | -9.52% |
| 2023 Q1 | 1.24 Billion USD | 12.16% |
| 2023 Q2 | 1.28 Billion USD | 2.76% |
| 2023 Q4 | 1.01 Billion USD | -18.12% |
| 2023 Q3 | 1.24 Billion USD | -3.09% |
| 2022 Q2 | 1.05 Billion USD | 9.3% |
| 2022 FY | - USD | 55.81% |
| 2022 Q4 | 1.11 Billion USD | -8.52% |
| 2022 Q1 | 962.2 Million USD | 8.85% |
| 2022 Q3 | 1.21 Billion USD | 15.67% |
| 2021 Q3 | 1.09 Billion USD | 4144.58% |
| 2021 FY | - USD | -12.52% |
| 2021 Q1 | 832.73 Million USD | -8.03% |
| 2021 Q4 | 884 Million USD | -19.58% |
| 2021 Q2 | -27.17 Million USD | -103.26% |
| 2020 Q2 | 847.84 Million USD | 25.93% |
| 2020 Q1 | 673.27 Million USD | -2.8% |
| 2020 FY | - USD | 118.68% |
| 2020 Q3 | 761.52 Million USD | -10.18% |
| 2020 Q4 | 905.41 Million USD | 18.89% |
| 2019 FY | - USD | 119.83% |
| 2019 Q3 | 88.17 Million USD | -74.22% |
| 2019 Q2 | 341.97 Million USD | 2.07% |
| 2019 Q4 | 692.69 Million USD | 685.61% |
| 2019 Q1 | 335.03 Million USD | 405.53% |
| 2018 Q1 | 225.66 Million USD | 79.99% |
| 2018 Q2 | 226.75 Million USD | 0.49% |
| 2018 Q3 | 144.48 Million USD | -36.28% |
| 2018 FY | - USD | 112.93% |
| 2018 Q4 | 66.27 Million USD | -54.13% |
| 2017 Q4 | 125.37 Million USD | 184.76% |
| 2017 Q1 | 280.29 Million USD | 584.17% |
| 2017 Q2 | 53.69 Million USD | -80.84% |
| 2017 FY | - USD | 1931.88% |
| 2017 Q3 | -147.91 Million USD | -375.49% |
| 2016 Q2 | 2.47 Million USD | 126.83% |
| 2016 FY | - USD | 103.24% |
| 2016 Q4 | 40.96 Million USD | 287.19% |
| 2016 Q3 | -21.88 Million USD | -983.57% |
| 2016 Q1 | -9.23 Million USD | 83.41% |
| 2015 Q2 | -167.62 Million USD | 7.07% |
| 2015 Q4 | -55.65 Million USD | 19.96% |
| 2015 FY | - USD | 22.57% |
| 2015 Q3 | -69.52 Million USD | 58.52% |
| 2015 Q1 | -180.37 Million USD | -17.69% |
| 2014 Q4 | -153.25 Million USD | -45.47% |
| 2014 FY | - USD | -221.1% |
| 2014 Q2 | -143.37 Million USD | 31.64% |
| 2014 Q1 | -209.74 Million USD | -174.29% |
| 2014 Q3 | -105.35 Million USD | 26.52% |
| 2013 Q1 | 387.59 Million USD | 601.53% |
| 2013 FY | - USD | 11983.19% |
| 2013 Q4 | 282.35 Million USD | 356.77% |
| 2013 Q2 | -55.38 Million USD | -114.29% |
| 2013 Q3 | -109.96 Million USD | -98.56% |
| 2012 Q1 | 92 Million USD | -60.82% |
| 2012 Q2 | -10.17 Million USD | -111.06% |
| 2012 FY | - USD | -98.12% |
| 2012 Q3 | -375 Thousand USD | 96.31% |
| 2012 Q4 | -77.28 Million USD | -20508.53% |
| 2011 Q2 | -162.18 Million USD | -6.16% |
| 2011 Q3 | 321.08 Million USD | 297.97% |
| 2011 Q4 | 234.81 Million USD | -26.87% |
| 2011 FY | - USD | 133.48% |
| 2011 Q1 | -152.78 Million USD | 22.49% |
| 2010 Q2 | -138.11 Million USD | 12.16% |
| 2010 Q3 | -191.94 Million USD | -38.97% |
| 2010 FY | - USD | -22.01% |
| 2010 Q4 | -197.12 Million USD | -2.7% |
| 2010 Q1 | -157.23 Million USD | -39.97% |
| 2009 Q1 | -134.33 Million USD | -3.33% |
| 2009 Q3 | -145.35 Million USD | -3.22% |
| 2009 Q2 | -140.82 Million USD | -4.83% |
| 2009 FY | - USD | -18.77% |
| 2009 Q4 | -112.33 Million USD | 22.72% |
| 2008 FY | - USD | -20.85% |
| 2008 Q4 | -130 Million USD | -7.53% |
| 2008 Q3 | -120.9 Million USD | -49.31% |
| 2008 Q2 | -80.97 Million USD | 10.01% |
| 2008 Q1 | -89.97 Million USD | -7.44% |
| 2007 FY | - USD | -87.27% |
| 2007 Q2 | -116.95 Million USD | -61.99% |
| 2007 Q4 | -83.74 Million USD | 20.39% |
| 2007 Q3 | -105.19 Million USD | 10.06% |
| 2007 Q1 | -72.19 Million USD | -185.64% |
| 2006 FY | - USD | -122.04% |
| 2006 Q1 | -44.97 Million USD | -62.65% |
| 2006 Q4 | -25.27 Million USD | 57.96% |
| 2006 Q3 | -60.12 Million USD | 15.94% |
| 2006 Q2 | -71.52 Million USD | -59.05% |
| 2005 FY | - USD | 12.48% |
| 2005 Q4 | -27.64 Million USD | -791.05% |
| 2005 Q3 | 4 Million USD | 111.25% |
| 2005 Q2 | -35.55 Million USD | -12.04% |
| 2005 Q1 | -31.73 Million USD | -26.83% |
| 2004 FY | - USD | -56.37% |
| 2004 Q3 | -24.26 Million USD | 22.41% |
| 2004 Q1 | -25.91 Million USD | 35.49% |
| 2004 Q4 | -25.01 Million USD | -3.1% |
| 2004 Q2 | -31.27 Million USD | -20.68% |
| 2003 Q3 | -85.25 Million USD | 102.44% |
| 2003 Q2 | -81.54 Million USD | -113.32% |
| 2003 Q4 | -102.25 Million USD | -2116.72% |
| 2003 FY | - USD | 29.4% |
| 2003 Q1 | 19.2 Million USD | -45.05% |
| 2002 Q1 | -20.78 Million USD | -504.27% |
| 2002 Q2 | -17.74 Million USD | 14.61% |
| 2002 FY | - USD | -290.56% |
| 2002 Q3 | -29.27 Million USD | -65.0% |
| 2002 Q4 | -26.36 Million USD | 9.99% |
| 2001 Q2 | -14.38 Million USD | -11.79% |
| 2001 Q1 | -12.87 Million USD | -11.47% |
| 2001 FY | - USD | -64.36% |
| 2001 Q4 | -7.43 Million USD | -244.56% |
| 2001 Q3 | -13.74 Million USD | 116.53% |
| 2000 Q1 | -15.94 Million USD | -495.36% |
| 2000 FY | - USD | 55.02% |
| 2000 Q4 | -11.7 Million USD | -697.1% |
| 2000 Q3 | -12.85 Million USD | -83.27% |
| 2000 Q2 | 11.56 Million USD | 169.6% |
| 1999 Q2 | -11.7 Million USD | 60.99% |
| 1999 Q3 | -14.6 Million USD | -39.08% |
| 1999 Q4 | 4.1 Million USD | 134.71% |
| 1999 FY | - USD | -16.85% |
| 1999 Q1 | -19.2 Million USD | -104.59% |
| 1998 Q2 | -8.5 Million USD | 44.81% |
| 1998 FY | - USD | -78.85% |
| 1998 Q1 | -11.4 Million USD | -180.0% |
| 1998 Q3 | -1 Million USD | 88.24% |
| 1998 Q4 | -10.9 Million USD | -990.0% |
| 1997 Q1 | -4.8 Million USD | 27.27% |
| 1997 Q2 | -400 Thousand USD | 91.67% |
| 1997 FY | - USD | 7.69% |
| 1997 Q4 | -5.5 Million USD | -17.02% |
| 1997 Q3 | -4.7 Million USD | -1075.0% |
| 1996 FY | - USD | 40.28% |
| 1996 Q3 | -6.6 Million USD | -218.18% |
| 1996 Q2 | -7.4 Million USD | 172.53% |
| 1996 Q4 | -4.8 Million USD | 15.38% |
| 1996 Q1 | -7.8 Million USD | -213.79% |
| 1995 Q1 | -4.9 Million USD | 16.22% |
| 1995 Q4 | -1.3 Million USD | 64.63% |
| 1995 Q3 | -7 Million USD | 25.45% |
| 1995 Q2 | -9.6 Million USD | -77.42% |
| 1995 FY | - USD | -36.06% |
| 1994 Q3 | -3 Million USD | 33.33% |
| 1994 FY | - USD | -662.16% |
| 1994 Q1 | -2.3 Million USD | -124.73% |
| 1994 Q2 | -4.5 Million USD | -95.65% |
| 1994 Q4 | -7.4 Million USD | -146.67% |
| 1993 Q4 | 9.7 Million USD | 504.35% |
| 1993 FY | - USD | 140.22% |
| 1993 Q1 | -2.7 Million USD | -15.38% |
| 1993 Q2 | 100 Thousand USD | 90.0% |
| 1993 Q3 | -2 Million USD | -666.67% |
| 1992 Q4 | -2.2 Million USD | -8.33% |
| 1992 Q2 | -1.5 Million USD | 4.76% |
| 1992 FY | - USD | -100.0% |
| 1992 Q1 | -1.5 Million USD | -31.25% |
| 1992 Q3 | -1.9 Million USD | -20.0% |
| 1991 FY | - USD | -12.2% |
| 1991 Q1 | 800 Thousand USD | 113.79% |
| 1991 Q3 | -1 Million USD | -44.44% |
| 1991 Q2 | -800 Thousand USD | -212.5% |
| 1991 Q4 | -1.2 Million USD | -23.08% |
| 1990 Q3 | 600 Thousand USD | 0.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q4 | -5.8 Million USD | -1066.67% |
| 1990 Q2 | 600 Thousand USD | 20.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akebia Therapeutics, Inc. | -6.86 Million USD | 67152.999% |
| Jaguar Health, Inc. | -33.13 Million USD | 13999.973% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 3126.213% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 8214.318% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 1883.289% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -4427.018% |
| ContextLogic Inc. | -324 Million USD | 1521.358% |
| MiMedx Group, Inc. | 40.51 Million USD | -11266.093% |
| MEI Pharma, Inc. | 26.38 Million USD | -17357.165% |
| AlloVir, Inc. | -190.14 Million USD | 2521.928% |
| Novavax, Inc. | -487.39 Million USD | 1044.87% |
| Aptorum Group Limited | -9.59 Million USD | 48075.846% |
| Ardelyx, Inc. | -55.35 Million USD | 8419.543% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 2721.476% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 167465.659% |
| Vaxcyte, Inc. | -464.88 Million USD | 1090.611% |
| Precigen, Inc. | -89.22 Million USD | 5261.276% |
| Pharming Group N.V. | 9.87 Million USD | -46525.494% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 2995.46% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 20331.966% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 27219.722% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 2072.274% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 25722.237% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 19199.284% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 19199.284% |
| Bicycle Therapeutics plc | -183.4 Million USD | 2611.014% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 5367.48% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 16000.287% |
| Acelyrin, Inc. | -381.52 Million USD | 1307.047% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -870448.204% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 13893.806% |
| Senti Biosciences, Inc. | -61.33 Million USD | 7608.152% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 4200.655% |
| AbCellera Biologics Inc. | -192.15 Million USD | 2496.569% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 15001.631% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 2883.927% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 1434741.745% |
| Chimerix, Inc. | -92.97 Million USD | 5053.213% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 14290.368% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 22944.387% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 10463.506% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 9927.152% |
| Elevation Oncology, Inc. | -41.46 Million USD | 11205.699% |
| Alkermes plc | 495.04 Million USD | -830.251% |
| Fortress Biotech, Inc. | -133.64 Million USD | 3545.897% |
| Fortress Biotech, Inc. | -133.64 Million USD | 3545.897% |
| Agenus Inc. | -145.92 Million USD | 3255.889% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 6054.256% |
| Dyadic International, Inc. | -8.22 Million USD | 56058.032% |
| ImmuCell Corporation | -2.5 Million USD | 184008.083% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 1582642.955% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 3631.026% |
| Lantern Pharma Inc. | -15.78 Million USD | 29271.411% |
| Immix Biopharma, Inc. | -16.13 Million USD | 28640.539% |
| Incyte Corporation | 919.42 Million USD | -400.878% |
| IO Biotech, Inc. | -91.22 Million USD | 5148.012% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 6584.005% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 23227.305% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 8126.362% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 3029.61% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 54949.929% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 6255.461% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 1311.994% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 952.929% |
| NextCure, Inc. | -59.03 Million USD | 7900.268% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 46299.839% |
| Onconetix, Inc. | -36.7 Million USD | 12645.93% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -205949.217% |
| Opthea Limited | -200.01 Million USD | 2402.384% |
| PDS Biotechnology Corporation | -40.08 Million USD | 11588.596% |
| PureTech Health plc | -11.62 Million USD | 39707.809% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 5967.02% |
| Seer, Inc. | -97.88 Million USD | 4804.705% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 35741188.981% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 20072.244% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 75390.859% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 15839.969% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 7933.305% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 19502.57% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 3871.57% |
| ChromaDex Corporation | -3.89 Million USD | 118363.996% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 66997.153% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 4192.274% |
| CRISPR Therapeutics AG | -202.7 Million USD | 2371.918% |
| Precision BioSciences, Inc. | -32.04 Million USD | 14472.386% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 2773.882% |
| Innoviva, Inc. | 248.96 Million USD | -1749.775% |
| Summit Therapeutics Inc. | 1 Million USD | -459959.94% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 7504.216% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 7145.361% |
| ESSA Pharma Inc. | -26.45 Million USD | 17507.47% |
| GlycoMimetics, Inc. | -39.12 Million USD | 11871.384% |
| GT Biopharma, Inc. | 5.97 Million USD | -76922.914% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 2328.039% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -5204.797% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 9091.195% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 46678.783% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 2046.226% |
| Aptose Biosciences Inc. | -52.26 Million USD | 8910.745% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 4374.23% |
| Soligenix, Inc. | -7.85 Million USD | 58743.677% |
| Century Therapeutics, Inc. | -121.2 Million USD | 3899.419% |
| Kura Oncology, Inc. | -164.95 Million USD | 2891.792% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 5849.457% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 45759.33% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 480940.814% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 106973.985% |
| Autolus Therapeutics plc | -156.77 Million USD | 3037.552% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 5539.834% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 6774.106% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 23202.237% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 2533.099% |
| GRI Bio, Inc. | -10.89 Million USD | 42357.295% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 102081.635% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 3859.163% |
| IGM Biosciences, Inc. | -253.35 Million USD | 1917.665% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 4536.951% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 12176.61% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 30138.666% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 29351.916% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 8201.328% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 4399.786% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1831.298% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 2474.561% |
| Verastem, Inc. | -83.16 Million USD | 5637.359% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 9206.225% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 3010.484% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 4136.498% |
| Histogen Inc. | -10.5 Million USD | 43946.52% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 32349.959% |
| Surrozen, Inc. | -41.13 Million USD | 11296.421% |
| Organovo Holdings, Inc. | -14.8 Million USD | 31203.607% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -143598278.547% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 7943.554% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 9078.048% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 21480.751% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 55331.437% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 2873.111% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 9449.052% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 19156.526% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 30689.094% |
| Apollomics, Inc. | -171.74 Million USD | 2781.386% |
| Amarin Corporation plc | -50.9 Million USD | 9147.272% |
| Mesoblast Limited | -61.33 Million USD | 7608.764% |
| Turnstone Biologics Corp. | -56.23 Million USD | 8289.352% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 3315.899% |
| Synaptogenix, Inc. | -8.3 Million USD | 55534.199% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 30122.818% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 7404.392% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 96212.547% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -1073275.614% |
| Exelixis, Inc. | 196.6 Million USD | -2242.397% |
| Better Therapeutics, Inc. | -38.26 Million USD | 12135.963% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 3356.653% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 1029.947% |
| NLS Pharmaceutics AG | -11.79 Million USD | 39141.495% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -1862724.413% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 15707.673% |
| Gritstone bio, Inc. | -126.86 Million USD | 3730.058% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 7186.558% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 115231.554% |
| Avid Bioservices, Inc. | -11.48 Million USD | 40211.489% |
| Insmed Incorporated | -654.73 Million USD | 803.364% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 204801.12% |
| MediWound Ltd. | -4.89 Million USD | 94218.128% |
| OmniAb, Inc. | -49.73 Million USD | 9360.22% |
| Alector, Inc. | -142.89 Million USD | 3322.854% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 5490.36% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 8931.019% |
| Zai Lab Limited | -366.57 Million USD | 1356.285% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 1684.52% |
| Aura Biosciences, Inc. | -83.69 Million USD | 5602.294% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 2144.493% |
| Immunic, Inc. | -99.11 Million USD | 4746.461% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 3597.532% |
| Veracyte, Inc. | -49.4 Million USD | 9420.569% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 65293.162% |
| FibroGen, Inc. | -261.4 Million USD | 1861.711% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 41435.607% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 65876.093% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 24704.545% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | -217.727% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 18215.018% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -11444.748% |
| TG Therapeutics, Inc. | 26.1 Million USD | -17544.444% |
| Galecto, Inc. | -37.51 Million USD | 12374.314% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 12135.019% |
| Fortrea Holdings Inc. | 167.3 Million USD | -2652.66% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 3529.55% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 16366.469% |
| XBiotech Inc. | -35.76 Million USD | 12975.916% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 7186.558% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 7157.778% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 4508.788% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 18038.61% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 11368.75% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 991.696% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 8320.489% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 8216188.919% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 4058.568% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 20872.633% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 2059.126% |
| NexImmune, Inc. | -28.16 Million USD | 16449.333% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 83443.77% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 39152.695% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 1.053% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 18236.421% |
| Scopus BioPharma Inc. | -11.71 Million USD | 39416.498% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 3759.393% |
| Ainos, Inc. | -8.77 Million USD | 52592.289% |
| Pluri Inc. | -20.22 Million USD | 22869.839% |
| Prothena Corporation plc | -190.1 Million USD | 2522.413% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 3692.256% |
| Celularity Inc. | -183.94 Million USD | 2603.561% |
| Rallybio Corporation | -72.37 Million USD | 6463.146% |
| Cue Biopharma, Inc. | -46.05 Million USD | 10100.0% |
| MeiraGTx Holdings plc | -57.05 Million USD | 8171.934% |
| Omeros Corporation | -163.61 Million USD | 2914.742% |
| Humacyte, Inc. | -96.45 Million USD | 4874.306% |
| Immunocore Holdings plc | -59.64 Million USD | 7820.498% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 23872.455% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 19000.882% |
| Blueprint Medicines Corporation | -474.61 Million USD | 1070.308% |
| CalciMedica, Inc. | -34.18 Million USD | 13569.829% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 6388.336% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 3769.57% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 2833.851% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 1924.636% |
| Pulmatrix, Inc. | -12.64 Million USD | 36516.258% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 14069.544% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 5305.557% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 1009.552% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 4649.918% |
| Cytokinetics, Incorporated | -456.68 Million USD | 1108.4% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 13899.179% |
| Nutriband Inc. | -5.12 Million USD | 90014.106% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 10742.448% |
| Vor Biopharma Inc. | -114.37 Million USD | 4126.545% |
| Roivant Sciences Ltd. | -996.51 Million USD | 562.131% |
| Evogene Ltd. | -23.2 Million USD | 19946.578% |
| ProKidney Corp. | -147.66 Million USD | 3218.596% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 7235.973% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 3007106.249% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 914.405% |
| CorMedix Inc. | -48.88 Million USD | 9520.085% |
| BioLineRx Ltd. | -57.06 Million USD | 8170.661% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 4220.689% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 2279901.98% |
| Atai Life Sciences N.V. | -36.31 Million USD | 12782.658% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 5891.467% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 5763.547% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 1771.561% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 15081.132% |
| MediciNova, Inc. | -9.87 Million USD | 46711.478% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 3756.633% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 301053.927% |
| GeoVax Labs, Inc. | -26.66 Million USD | 17368.138% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 2146.837% |
| Biomea Fusion, Inc. | -124.62 Million USD | 3795.394% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 1494.079% |
| Mereo BioPharma Group plc | -26.05 Million USD | 17774.24% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 2519.473% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 2102.766% |
| Absci Corporation | -95.45 Million USD | 4924.371% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 15437.885% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 4399.184% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 2072.451% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 20249.639% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 2315.786% |
| Allakos Inc. | -189.91 Million USD | 2524.874% |
| Imunon, Inc. | -19.87 Million USD | 23266.995% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 4344.737% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -4151.32% |
| BioAtla, Inc. | -122.24 Million USD | 3867.312% |
| NLS Pharmaceutics AG | -11.79 Million USD | 39141.495% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 29318.958% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 1633.569% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 11211.057% |
| XOMA Corporation | -39.36 Million USD | 11799.609% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 4739.813% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 4014.322% |
| aTyr Pharma, Inc. | -52.17 Million USD | 8925.942% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 5594.482% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 3198.412% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 2063.294% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 33830.316% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 57362.226% |
| Akari Therapeutics, Plc | -16.8 Million USD | 27508.642% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -2440309.95% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -918.969% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 72184.369% |
| UroGen Pharma Ltd. | -63.83 Million USD | 7314.676% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 6880.829% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 63506.201% |
| Orgenesis Inc. | -60.71 Million USD | 7684.571% |
| Entera Bio Ltd. | -8.8 Million USD | 52408.042% |
| GH Research PLC | -41.15 Million USD | 11290.436% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 18146.162% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 5700.185% |
| Xencor, Inc. | -125.87 Million USD | 3758.579% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 322921.923% |
| Replimune Group, Inc. | -230.19 Million USD | 2100.539% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 22945.953% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 42187.37% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 72184.369% |
| Portage Biotech Inc. | -18.19 Million USD | 25404.687% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 301053.927% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 4503.35% |
| OncoCyte Corporation | -23.12 Million USD | 20016.101% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 40852.677% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 40296.079% |
| Purple Biotech Ltd. | -22.22 Million USD | 20820.81% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 71943.994% |
| scPharmaceuticals Inc. | -46.06 Million USD | 10098.046% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 25957.845% |
| HilleVax, Inc. | -132.46 Million USD | 3576.515% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 43410.449% |
| Tharimmune, Inc. | -9.3 Million USD | 49604.498% |
| Genprex, Inc. | -31.06 Million USD | 14926.517% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 2555.766% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 14787.759% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 602874.869% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -3051641.505% |
| OKYO Pharma Limited | -15.74 Thousand USD | 29247134.302% |
| Savara Inc. | -59.13 Million USD | 7887.868% |
| Curis, Inc. | -45.13 Million USD | 10302.264% |
| Daré Bioscience, Inc. | -30.7 Million USD | 15099.91% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 30415.023% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 64373.552% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 17326.004% |
| BeiGene, Ltd. | -1.12 Billion USD | 509.493% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 28350.681% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 1169.529% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 5197.631% |
| Erasca, Inc. | -121.31 Million USD | 3896.225% |
| bluebird bio, Inc. | -167.16 Million USD | 2854.949% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 102466.076% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -1384.189% |
| DBV Technologies S.A. | -85.98 Million USD | 5456.005% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 102466.076% |
| Moderna, Inc. | -3.28 Billion USD | 240.274% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 10908.045% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 81636.827% |
| Molecular Templates, Inc. | 1.43 Million USD | -321941.958% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 7794.313% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 1511.573% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 3459.278% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 9822.586% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 3412.283% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 2337.054% |
| MacroGenics, Inc. | 2.01 Million USD | -228219.286% |
| RenovoRx, Inc. | -11.39 Million USD | 40531.958% |
| Adicet Bio, Inc. | -136.53 Million USD | 3472.908% |
| Prime Medicine, Inc. | -193.75 Million USD | 2476.767% |
| Aditxt, Inc. | -25.45 Million USD | 18189.428% |
| Adagene Inc. | -14.95 Million USD | 30902.396% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 63097.787% |
| Quantum-Si incorporated | -91.8 Million USD | 5116.339% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | -546.426% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -3541.77% |
| SciSparc Ltd. | -5.28 Million USD | 87286.672% |
| Vericel Corporation | 2.86 Million USD | -160696.089% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 4837088.488% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 21330.505% |
| Generation Bio Co. | -133.3 Million USD | 3554.764% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 5646.429% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 5453.452% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 2124.851% |
| Invivyd, Inc. | -196.61 Million USD | 2442.242% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 1330.833% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 49752.833% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -16859.564% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 44875.887% |
| 2seventy bio, Inc. | -206.41 Million USD | 2331.007% |
| ADMA Biologics, Inc. | 5.12 Million USD | -89845.313% |
| Clene Inc. | -43.24 Million USD | 10750.077% |
| Capricor Therapeutics, Inc. | -23 Million USD | 20114.797% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 9599.763% |
| GeoVax Labs, Inc. | -26.66 Million USD | 17368.138% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 1637.291% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 12638.202% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -19435.91% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -93687.39% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 14277.698% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 3007.25% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 772.975% |
| Evaxion Biotech A/S | -21.4 Million USD | 21616.61% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 7033.976% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 2215.689% |
| Trevena, Inc. | -35.28 Million USD | 13150.329% |
| Surrozen, Inc. | -41.13 Million USD | 11296.421% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 5886.009% |
| Cingulate Inc. | -22.95 Million USD | 20164.455% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 61823.63% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 12452.01% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 56080.942% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 4603.158% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 6889.627% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 7989.399% |
| Clearmind Medicine Inc. | -8.71 Million USD | 52968.539% |
| Kronos Bio, Inc. | -121.83 Million USD | 3880.021% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 6294.614% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 188728.393% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4667.427% |
| Statera Biopharma, Inc. | 38.93 Million USD | -11727.933% |
| ImmunityBio, Inc. | -436.18 Million USD | 1155.798% |
| Korro Bio, Inc. | -80.9 Million USD | 5792.178% |
| Kineta, Inc. | -15.71 Million USD | 29406.351% |
| BioVie Inc. | -31.95 Million USD | 14513.678% |
| Codexis, Inc. | -49.28 Million USD | 9444.399% |
| Celularity Inc. | -183.94 Million USD | 2603.561% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 2179.003% |
| Celcuity Inc. | -58.3 Million USD | 7997.794% |
| Virax Biolabs Group Limited | -6.6 Million USD | 69779.22% |
| Cibus, Inc. | -314.58 Million USD | 1563.897% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 13751.914% |
| IN8bio, Inc. | -28.5 Million USD | 16256.329% |
| Kodiak Sciences Inc. | -259.02 Million USD | 1877.912% |
| Annexon, Inc. | -141.57 Million USD | 3352.834% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 4189.912% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 7273.656% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 16573.618% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 2102.174% |
| Eyenovia, Inc. | -24.1 Million USD | 19203.929% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -10183.137% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 1421458.025% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 6339.77% |
| Arcellx, Inc. | -64.14 Million USD | 7279.359% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 10330.595% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 3829.632% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 15012.247% |
| Moolec Science SA | -52.07 Million USD | 8943.308% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 9023.769% |
| Geron Corporation | -174.78 Million USD | 2734.825% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 11494.215% |
| Royalty Pharma plc | 1.88 Billion USD | -144.013% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 3950.727% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 49489.474% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 22303.628% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 2872.881% |
| Humacyte, Inc. | -96.45 Million USD | 4874.306% |
| Structure Therapeutics Inc. | -102.45 Million USD | 4594.676% |
| 89bio, Inc. | -134.46 Million USD | 3524.883% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 5938.605% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -113552.517% |
| Genelux Corporation | -24.16 Million USD | 19157.314% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 13724.852% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 2917.256% |
| Notable Labs, Ltd. | -14.4 Million USD | 32080.556% |
| Liquidia Corporation | -70.05 Million USD | 6674.067% |
| Mustang Bio, Inc. | -48.06 Million USD | 9681.591% |
| Immunovant, Inc. | -269.97 Million USD | 1805.769% |
| Quantum-Si incorporated | -91.8 Million USD | 5116.339% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 6587.476% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 23951.253% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 4614.371% |
| Acasti Pharma Inc. | -11.3 Million USD | 40850.376% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 20794.513% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 30138.666% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 2287.608% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 107941.454% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 29100.0% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 16103.614% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 12536.403% |
| PepGen Inc. | -83.58 Million USD | 5609.799% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 15708.731% |
| United Therapeutics Corporation | 1.38 Billion USD | -232.074% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 20212.679% |
| Solid Biosciences Inc. | -93.43 Million USD | 5028.827% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 96609.949% |
| Immuneering Corporation | -58.06 Million USD | 8031.685% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -143598278.547% |
| Silo Pharma, Inc. | -3.62 Million USD | 127097.469% |
| Belite Bio, Inc | -31.52 Million USD | 14706.236% |
| XOMA Corporation | -39.36 Million USD | 11799.609% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 6927.88% |
| Bionomics Limited | -9.83 Million USD | 46915.11% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 5583.36% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 13407.519% |
| uniQure N.V. | -253.1 Million USD | 1919.518% |
| Cassava Sciences, Inc. | -95.68 Million USD | 4912.775% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 63097.787% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 3656.029% |
| Forte Biosciences, Inc. | -32.47 Million USD | 14279.882% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 57304.092% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 16419.501% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 1421458.025% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 41435.607% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 29061.701% |
| Altimmune, Inc. | -87.93 Million USD | 5337.05% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 5101.358% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 13407.519% |
| Compugen Ltd. | -12.51 Million USD | 36894.503% |
| Peak Bio, Inc. | -1356.23 USD | 339559024.371% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 9576.11% |
| Benitec Biopharma Inc. | -22.49 Million USD | 20576.656% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 2000.596% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 16234.254% |
| Zura Bio Limited | -60.56 Million USD | 7703.983% |
| PolyPid Ltd. | -20.26 Million USD | 22827.138% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 29595.933% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 16234.254% |
| Instil Bio, Inc. | -146.12 Million USD | 3251.613% |
| argenx SE | -216.02 Million USD | 2231.81% |
| Immunome, Inc. | -28.27 Million USD | 16389.484% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 9600.547% |
| Verona Pharma plc | -52.46 Million USD | 8877.229% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 4959.241% |
| Shattuck Labs, Inc. | -87.61 Million USD | 5356.178% |
| CervoMed Inc. | -2.17 Million USD | 212138.083% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 3867.22% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 36381.415% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 9659.513% |
| Moolec Science SA | -52.07 Million USD | 8943.308% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 26968.17% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 3631.838% |
| AnaptysBio, Inc. | -143.16 Million USD | 3316.73% |
| Design Therapeutics, Inc. | -66.32 Million USD | 7043.385% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 5786.345% |
| NeurAxis, Inc. | -6.66 Million USD | 69200.509% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 12299.205% |
| Lumos Pharma, Inc. | -36.57 Million USD | 12692.836% |
| Achilles Therapeutics plc | -70.44 Million USD | 6637.577% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 4959.241% |
| 180 Life Sciences Corp. | -22.13 Million USD | 20905.974% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -78901.627% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 188728.393% |
| Nutriband Inc. | -5.12 Million USD | 90014.106% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 4296.158% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 8407.837% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 9210.188% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 7154.859% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 8610.821% |
| Palisade Bio, Inc. | -12.28 Million USD | 37598.575% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 10248.977% |
| Beam Therapeutics Inc. | -156.47 Million USD | 3043.128% |
| Neurogene Inc. | -52.28 Million USD | 8907.711% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 3474.02% |
| AEON Biopharma, Inc. | -48.36 Million USD | 9622.549% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 5050.87% |
| Sesen Bio, Inc. | -50.84 Million USD | 9158.222% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 5720.759% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 37388.999% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 1177.411% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 4477.691% |
| Athira Pharma, Inc. | -116.7 Million USD | 4046.085% |
| Vaccinex, Inc. | -19.74 Million USD | 23419.83% |
| HCW Biologics Inc. | -23.57 Million USD | 19633.377% |
| XOMA Corporation | -39.36 Million USD | 11799.609% |
| Nektar Therapeutics | -243.1 Million USD | 1994.31% |
| Arvinas, Inc. | -394.8 Million USD | 1266.464% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -2440309.95% |
| Merus N.V. | -149.2 Million USD | 3186.45% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 5025.874% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 14831.926% |
| Rezolute, Inc. | -68.42 Million USD | 6830.485% |
| Clene Inc. | -43.24 Million USD | 10750.077% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 29960.869% |
| BeyondSpring Inc. | -21.54 Million USD | 21479.759% |
| Synlogic, Inc. | -55.16 Million USD | 8448.652% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 38213.051% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 43373.821% |
| Peak Bio, Inc. | -1356.23 USD | 339559024.371% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 14285.122% |
| Krystal Biotech, Inc. | 17.9 Million USD | -25621.626% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 3988.772% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 1449.13% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 100073.255% |
| MannKind Corporation | 15.12 Million USD | -30339.553% |
| Ikena Oncology, Inc. | -74.39 Million USD | 6290.035% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 36669.523% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -22555.581% |
| Gossamer Bio, Inc. | -172.15 Million USD | 2775.078% |
| CohBar, Inc. | -12.06 Million USD | 38267.512% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 18153.236% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 15437.885% |
| Legend Biotech Corporation | -477.87 Million USD | 1063.687% |
| Mural Oncology plc | -192.72 Million USD | 2489.581% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 4137.737% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 28623.524% |
| Disc Medicine, Inc. | -91.02 Million USD | 5159.269% |
| Champions Oncology, Inc. | -5.05 Million USD | 91219.905% |
| REGENXBIO Inc. | -239.46 Million USD | 2023.128% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 43066.222% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 8359.56% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 11978.787% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 4182.407% |
| Vaxart, Inc. | -74.72 Million USD | 6263.029% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 13179.872% |
| Cellectis S.A. | -98.09 Million USD | 4794.633% |
| Longeveron Inc. | -20.06 Million USD | 23057.129% |
| Repare Therapeutics Inc. | -114.27 Million USD | 4129.998% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 1148.552% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 6255.697% |
| Revolution Medicines, Inc. | -430.58 Million USD | 1169.529% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 73326.268% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 15057.29% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 6274.018% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -93826.168% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 42099.088% |
| Denali Therapeutics Inc. | -179.97 Million USD | 2658.828% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 4837088.488% |
| Veru Inc. | -89.97 Million USD | 5218.278% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 17233.715% |
| Cingulate Inc. | -22.95 Million USD | 20164.455% |
| Passage Bio, Inc. | -98.34 Million USD | 4782.889% |
| Context Therapeutics Inc. | -25.06 Million USD | 18476.276% |
| Exicure, Inc. | -15.53 Million USD | 29736.399% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 2334.84% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 12554.565% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 77334.815% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 2833.64% |
| Nuvalent, Inc. | -149.49 Million USD | 3180.566% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 56727.705% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 5461.492% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 15360.123% |
| OmniAb, Inc. | -49.73 Million USD | 9360.22% |
| Anew Medical, Inc. | -1.3 Million USD | 354117.404% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 37346.846% |
| Lipocine Inc. | -16.32 Million USD | 28313.528% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 7007.455% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 6297.865% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 12176.61% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 11903.968% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 20860.041% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 944.882% |
| Ocugen, Inc. | -64.82 Million USD | 7203.83% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 5074.83% |
| Q32 Bio Inc. | -86.5 Million USD | 5423.808% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 27306.239% |
| Alumis Inc. Common Stock | -156.89 Million USD | 3035.305% |
| Equillium, Inc. | -12.13 Million USD | 38040.353% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 7975.906% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 58368.969% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 24516.555% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 9962.932% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 4430.434% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 25846.663% |
| Dominari Holdings Inc. | -22.44 Million USD | 20622.282% |
| Edesa Biotech, Inc. | -8.19 Million USD | 56328.573% |
| vTv Therapeutics Inc. | -25.41 Million USD | 18222.147% |
| Bio-Techne Corporation | 326.66 Million USD | -1309.771% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 1296.579% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -2028.204% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 3612.524% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 12403.171% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 3147.763% |
| Nkarta, Inc. | -120.48 Million USD | 3922.345% |
| BioCardia, Inc. | -11.56 Million USD | 39937.37% |
| Iterum Therapeutics plc | -34.58 Million USD | 13417.525% |